Top

Published in:

01-09-2019 | Glioblastoma | Clinical Study

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study

Authors: M. C. Morisse, N. Etienne-Selloum, D. Bello-Roufai, M. Blonski, L. Taillandier, V. Lorgis, G. Noël, G. Ahle, A. Durán-Peña, M. Boone, B. Chauffert

Published in: Journal of Neuro-Oncology | Issue 2/2019

Abstract

Purpose

Recurrence of glioblastoma (GB) occurs in most patients after standard concomitant temozolomide-based radiochemotherapy (CTRC). Bevacizumab (BV), an anti-VEGF antibody, has an effect on progression-free survival (PFS) but not on overall survival (OS). However, a small part of the patients experience a survival, longer than expected. This retrospective study aims to characterize long responder (LR) patients treated with BV for a first or second GBM recurrence.

Methods

Medical records from patients (814) who received BV for a first or second recurrence of primary glioblastoma between September 2010 and September 2015, and initially treated by CTRC were analyzed. Patients, who had at least a stable disease according to RANO criteria at 12 months from the start of BV, were included. Patients who had, a secondary GB, or received BV in neoadjuvant or adjuvant setting were excluded.

Results

We focused on 65 LR patients without progression 12 months after the first injection of BV (8%). Median PFS was 21.7 months [95% CI (19.3; 27.2)] and median OS was 31.1 months [95% CI (24.3; 37.5)] from the start of BV. No prognostic factor was associated with OS in multivariate analysis. Karnofsky performance status, neurological status and corticosteroid dose were stable at 12 months.

Conclusions

Our results highlight that among patients receiving bevacizumab in first or second recurrence, one patient out of twelve could be classified as LR. A median OS of 31.1 months from the start of BV could be expected in this subpopulation. These findings reinforce the potential benefit of the use of BV in the situation of recurrence.

256 words

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622PubMed

Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622PubMedPubMedCentral

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708PubMedPubMedCentral

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722PubMed

Wong ET, Gautam S, Malchow C et al (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw JNCCN 9(4):403–407

Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963PubMed

Lombardi G, Pambuku A, Bellu L et al (2017) Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 111:94–102PubMed

Schaub C, Tichy J, Schäfer N et al (2016) Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol 129(1):93–100PubMed

10.

Bi WL, Beroukhim R (2014) Beating the odds: extreme long-term survival with glioblastoma. Neuro-Oncol 16(9):1159–1160PubMedPubMedCentral

11.

Gately L, McLachlan S-A, Philip J et al (2018) Long-term survivors of glioblastoma: a closer look. J Neurooncol 136(1):155–162PubMed

12.

Johnson DR, Omuro AMP, Ravelo A et al (2018) Overall survival in patients with glioblastoma before and after bevacizumab approval. Curr Med Res Opin 34(5):813–820PubMed

13.

Chen C, Ravelo A, Yu E et al (2015) Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. J Neurooncol 122(3):595–605PubMedPubMedCentral

14.

Gramatzki D, Roth P, Rushing EJ et al (2018) Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdy106 CrossRef

15.

Bronnimann C, Izquierdo C, Cartalat S et al (2018) Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. J Neurooncol. https://doi.org/10.1007/s11060-018-2780-1 CrossRefPubMed

16.

Balaña C, Estival A, Pineda E et al (2017) Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neuro-Oncol Pract 4(1):15–23

17.

Hertenstein A, Hielscher T, Menn O et al (2016) Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. J Neurooncol 129(3):533–539PubMed

18.

Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro-Oncol 16(6):823–828PubMedPubMedCentral

19.

Reardon DA, Herndon JE, Peters KB et al (2012) Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 107(9):1481–1487PubMedPubMedCentral

20.

Hamza MA, Mandel JJ, Conrad CA et al (2014) Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135–140PubMedPubMedCentral

21.

Piccioni DE, Selfridge J, Mody RR et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncol 16(6):815–822PubMedPubMedCentral

22.

Wiestler B, Radbruch A, Osswald M et al (2014) Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 117(1):85–92PubMed

23.

Franceschi E, Lamberti G, Paccapelo A et al (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol 20:18. https://doi.org/10.1007/s11060-018-2873-x CrossRef

24.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28(11):1963–1972PubMed

25.

Ellingson BM, Chung C, Pope WB et al (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504PubMed

26.

Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495PubMedPubMedCentral

27.

Duerinck J, Clement PM, Bouttens F et al (2015) Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol 262(3):742–751PubMed

28.

Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113(11):1642PubMedPubMedCentral

29.

Flieger M, Ganswindt U, Schwarz SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117(2):337–345PubMed

30.

Palmer JD, Bhamidipati D, Song A et al (2018) Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J Neurooncol 140(3):623–628PubMed

31.

Brandes AA, Bartolotti M, Tosoni A et al (2015) Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20(2):166–175PubMedPubMedCentral

32.

Vredenburgh JJ, Cloughesy T, Samant M et al (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329–1334PubMedPubMedCentral

33.

Taphoorn MJB, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 33(19):2166–2175PubMed

34.

Dirven L, van den Bent MJ, Bottomley A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer Oxf Engl 1990 51(10):1321–1330

35.

Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115(2):267–276PubMed

36.

Lv S, Teugels E, Sadones J et al (2011) Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 31(12):4457–4463PubMed

37.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y et al (2016) Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76(3):525–534PubMed

38.

Gerber NK, Goenka A, Turcan S et al (2014) Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncol 16(9):1186–1195PubMedPubMedCentral

39.

Amelot A, De Cremoux P, Quillien V et al (2015) IDH-Mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE 10(7):e0130596PubMedPubMedCentral

40.

Hartmann C, Hentschel B, Simon M et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19(18):5146–5157PubMed

41.

Levin VA, Mendelssohn ND, Chan J et al (2015) Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 122(1):145–150PubMed

42.

Lorgis V, Maura G, Coppa G et al (2012) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 107(2):351–358PubMed

43.

Ajlan A, Thomas P, Albakr A et al (2017) Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 135(1):99–105PubMed

44.

Batchelor TT, Gerstner ER, Emblem KE et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064PubMed

Title: Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
Authors: M. C. Morisse
N. Etienne-Selloum
D. Bello-Roufai
M. Blonski
L. Taillandier
V. Lorgis
G. Noël
G. Ahle
A. Durán-Peña
M. Boone
B. Chauffert
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Bevacizumab
Published in: Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03245-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Phase II study of Dovitinib in recurrent glioblastoma

Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging

Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery

Retraction Note to: Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center